Hematology

Sutimlimab shows promising results in long-term relief for rare autoimmune hemolytic anemia

The Phase 3 study of sutimlimab, a C1s inhibitor, for the treatment of Cold Agglutinin Disease (CAD) showed promising results in improving patient quality of life. The study's long-term evaluation demonstrated sustained alleviation of CAD disease burden over 2 years of treatment with sutimlimab. Patients experienced significant relief from fatigue,...